News

@onclive
urologytimes.com > view > pearls-perspectives-driving-innovation-in-prosthetic-urology-with-gerard-henry-md

Pearls & Perspectives: Driving Innovation in Prosthetic Urology, with Gerard Henry, MD

Pearls & Perspectives: Driving Innovation in Prosthetic Urology, with Gerard Henry, MD1+ hour, 35+ min ago   (299+ words) Pearls & Perspectives: Driving Innovation in Prosthetic Urology, with Gerard Henry, MD'Urology Times Welcome back to Pearls & Perspectives! In this special Urology on the Beach edition of Pearls & Perspectives, host Amy Pearlman, MD, sits down with Gerard Henry, MD, to reflect…...

@onclive
urologytimes.com > view > kate-kraft-md-on-finding-your-leadership-flow-

Kate Kraft, MD, on finding your “leadership flow”

Kate Kraft, MD, on finding your “leadership flow”19+ hour, 2+ min ago   (294+ words) Kate Kraft, MD, on finding your "leadership flow'Urology Times In this interview, Kate H. Kraft, MD, MHPE, FACS, FAAP, discusses her session on helping early-career women find their "leadership flow," which she presented at the Society of Women in Urology (SWIU)…...

@onclive
urologytimes.com > view > eu-agency-recommends-expanded-approval-of-niraparib-abiraterone-dual-tablet-in-mhspc

EU agency recommends expanded approval of niraparib/abiraterone dual tablet in mHSPC

EU agency recommends expanded approval of niraparib/abiraterone dual tablet in mHSPC1+ day, 4+ hour ago   (220+ words) The tablet was previously approved by the FDA in December 2025 for adult patients with deleterious or suspected deleterious'BRCA2-mutated mHSPC.2 In total, the trial enrolled 696 patients who were randomly assigned 1:1 to receive abiraterone plus AAP (n = 348) or placebo plus AAP…...

@onclive
urologytimes.com > view > head-to-head-analysis-shows-os-benefit-with-apalutamide-vs-darolutamide-in-mcspc

Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC

Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC1+ day, 6+ hour ago   (195+ words) The results were presented at the 36th International Prostate Cancer Update in Vail, Colorado. In total, the retrospective intention-to-treat analysis included 1747 patients, of whom 1460 received apalutamide without docetaxel and 287 received darolutamide without docetaxel. The median time between metastasis and initiation of…...

@onclive
urologytimes.com > shorts > mathew-d-sorensen-md-ms-facs-on-how-break-wave-lithotripsy-works-without-anesthesia

Mathew D. Sorensen, MD, MS, FACS, on how Break Wave lithotripsy works without anesthesia

Mathew D. Sorensen, MD, MS, FACS, on how Break Wave lithotripsy works without anesthesia1+ day, 14+ hour ago   (61+ words) Mathew D. Sorensen, MD, MS, FACS, on how Break Wave lithotripsy works without anesthesia'Urology Times Trending on Urology Times Inside Break Wave: A new noninvasive approach to stone care Ridwan I. Alam, MD, MPH, discusses integrating PHI into prostate cancer diagnostic pathways…...

@onclive
urologytimes.com > view > inside-break-wave-a-new-noninvasive-approach-to-stone-care

Inside Break Wave: A new noninvasive approach to stone care

Inside Break Wave: A new noninvasive approach to stone care2+ day, 3+ hour ago   (352+ words) Inside Break Wave: A new noninvasive approach to stone care'Urology Times In this video, Mathew D. Sorensen, MD, MS, FACS, a professor of urology at the University of Washington and director of the Comprehensive Metabolic Stone Clinic at the Puget Sound…...

@onclive
urologytimes.com > view > evidence-informed-management-of-metastatic-castration-sensitive-prostate-cancer

Evidence-informed management of metastatic castration-sensitive prostate cancer | Urology Times

Evidence-informed management of metastatic castration-sensitive prostate cancer | Urology Times4+ day, 13+ hour ago   (524+ words) A recurring theme was the debate between upfront combination therapy and sequential escalation. This summary was generated by artificial intelligence and edited by humans for clarity. There was broad agreement that androgen deprivation therapy (ADT) continues to serve as the…...

@onclive
urologytimes.com > view > pearls-perspectives-innovation-and-evolving-pathways-in-female-pelvic-medicine-with-raveen-syan-md-fpmrs

Pearls & Perspectives: Innovation and Evolving Pathways in Female Pelvic Medicine, with Raveen Syan, MD, FPMRS | Urology Times

Pearls & Perspectives: Innovation and Evolving Pathways in Female Pelvic Medicine, with Raveen Syan, MD, FPMRS | Urology Times4+ day, 13+ hour ago   (149+ words) The conversation highlights the steady pace of innovation in urogynecology. Welcome back to'Pearls & Perspectives! In this special Urology on the Beach edition of Pearls & Perspectives, host Amy Pearlman, MD, sits down with Raveen Syan, MD, FPMRS, to discuss the rapidly…...

@onclive
urologytimes.com > view > farah-rahman-md-on-monitoring-resident-wellness-using-biofeedback

Farah Rahman, MD, on monitoring resident wellness using biofeedback

Farah Rahman, MD, on monitoring resident wellness using biofeedback4+ day, 23+ hour ago   (351+ words) Farah Rahman, MD, on monitoring resident wellness using biofeedback'Urology Times In an interview at the Society of Women in Urology (SWIU) 15th Annual Clinical Mentoring Conference in Nashville, Tennessee, Farah Rahman, MD, MPH, discussed the design and key findings from the…...

@onclive
urologytimes.com > view > pearls-perspectives-innovation-and-evolving-pathways-in-female-pelvic-medicine-with-raveen-syan-md-fpmrs

Pearls & Perspectives: Innovation and Evolving Pathways in Female Pelvic Medicine, with Raveen Syan, MD, FPMRS

Pearls & Perspectives: Innovation and Evolving Pathways in Female Pelvic Medicine, with Raveen Syan, MD, FPMRS5+ day, 56+ min ago   (149+ words) The conversation highlights the steady pace of innovation in urogynecology. Welcome back to'Pearls & Perspectives! In this special Urology on the Beach edition of Pearls & Perspectives, host Amy Pearlman, MD, sits down with Raveen Syan, MD, FPMRS, to discuss the rapidly…...